Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Povorcitinib in Healthy Japanese Participants
NCT05068466Phase 1Completed
- Sponsor
- Incyte
- Start
- Oct 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of povorcitinib in hidradenitis suppurativa (HS), Vitiligo, prurigo nodularis (PN) and 1 more (4 arms), sponsored by Incyte. Primary endpoints: Treatment Emergent Adverse Events at 3 months, Maximum Observed Plasma Concentration at 17 Days and 5 more. Started Oct 2021; status: completed.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)Vitiligoprurigo nodularis (PN)chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT05068466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05068466.